Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
AUTOR(ES)
Anderson, Peter L.
FONTE
Oxford University Press
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2760462Documentos Relacionados
- Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo
- Study of CYP3A5 gene expression and polymorphisms in hypercholesterolemic individuals treated with atorvastatin
- CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin
- The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole
- A proposed classification of genetically determined mosaicism in man.